

Application No.: 09/537,118

Docket No.: N9810.0007/P007

AMENDMENTS TO THE CLAIMS

Claims 1-26 canceled.

27. (Currently amended) The method composition of claim 80[[26]], wherein the spray composition further comprises comprising a flavoring agent in the amount of between 0.1 and 10 percent by weight of the total composition.

28. (Currently amended) The method composition of claim 27, wherein the polar solvent is present in an amount between 27 and 98 percent by weight of the total composition, the active compound is present in an amount between 0.005 and 55 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.5 and 8 percent by weight of the total composition.

29. (Currently amended) The method composition of claim 80[[28]], wherein the polar solvent is present in an amount between 59 and 97 percent by weight of the total composition, the active compound is present in an amount between 0.01 and 40 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the total composition.

30. (Currently amended) The method composition of claim 80[[26]], wherein the polar solvent is selected from the group consisting of comprises a polyethylene glycols having a molecular weight between 400 and 1000, C<sub>2</sub> to C<sub>8</sub> mono- and poly-alcohols or C<sub>7</sub> to C<sub>18</sub> alcohols of linear or branched configuration.

31. (Currently amended) The method composition of claim 80[[26]], wherein the polar solvent comprises aqueous polyethylene glycol.

32. (Currently amended) The method composition of claim 80[[26]], wherein the polar solvent comprises aqueous ethanol.

Application No.: 09/537,118

Docket No.: N9810.0007/P007

33. (Currently amended) The method composition of claim 80[[26]], wherein the active compound is selected from the group consisting of comprises cyclosporine, clozapine, zidevudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost thromethamine, valcrian, or a pharmaceutically acceptable salt thereof.

34. (Currently amended) The method composition of claim 80[[27]], wherein the flavoring agent comprises a synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners or mixture thereof.

Claims 35 – 53 canceled.

54. (Currently amended) The method composition of claim 81[[53]], further comprising a flavoring agent in the amount between 0.1 and 10 percent by weight of the total composition.

55. (Currently amended) The method composition of claim 54, wherein the non-polar solvent is present in an amount between 69 and 99 percent by weight of the total composition, the active compound is clozapine in an amount from between 0.5 and 30 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.1 and 5 percent by weight of the total composition.

56. (Currently amended) The method composition of claim 81[[53]], wherein the active compound is selected from the group consisting of comprises cyclosporine, clozapine, zidovudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost thromethamine, valerian or a pharmaceutically acceptable salt thereof.

57. (Currently amended) The method composition of claim 54, wherein the flavoring agent comprises a synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweetener or a mixture thereof.

58. (Currently amended) The method composition of claim 81[[53]], wherein the solvent is selected from the group consisting of comprises a (C<sub>2</sub>-C<sub>24</sub>) fatty acid (C<sub>2</sub>-C<sub>6</sub>)

Application No.: 09/537,118

Docket No.: N9810.0007/P007

esters,  $C_7$ - $C_{18}$  hydrocarbons of linear or branched configuration, and  $C_2$ - $C_6$  alkanoyl esters or triglycerides of a  $C_2$ - $C_6$  carboxylic acid.

59. (Currently amended) The method composition of claim 81[[53]], wherein the solvent comprises one or more fatty acid esters.

Claims 60 – 79 canceled.

80. (New) A method for administering an effective amount of a pharmacologically active compound to a mammal to provide transmucosal absorption of a pharmacologically effective amount of the active compound through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising:

spraying the oral mucosa of the mammal with a buccal spray composition, containing a pharmacologically active compound dissolved in a pharmacologically acceptable solvent, comprising in weight percent of the composition:

an active compound in an amount of between 0.001 and 60 percent selected from the group consisting of a biologically active peptide, central nervous system active amine, sulfonyl urea, antibiotic, antifungal, sleep inducer, antiasthmatic, antiemetic, antiviral, histamine H-2 receptor antagonist, barbiturate, prostaglandin or bronchial dilator; and

a polar solvent in an amount between 30 and 99 percent.

81. (New) A method for administering an effective amount of a pharmacologically active compound to a mammal to provide transmucosal absorption of a pharmacologically effective amount of the active compound through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising:

Application No.: 09/537,118

Docket No.: N9810.0007/P007

spraying the oral mucosa of the mammal with a buccal spray composition, containing a pharmacologically active compound dissolved in a pharmacologically acceptable solvent, comprising in weight percent of the composition:

an active compound in an amount between 0.005 and 55 percent comprising a biologically active peptide, central nervous system active amine, sulfonyl urea, antibiotic, antifungal, sleep inducer, antiasthmatic, antiemetic, antiviral, histamine H-2 receptor antagonist, barbiturate, prostaglandin or bronchial dilator; and

a non-polar solvent in an amount between 30 and 99 percent.

82. (New) A method for administering an effective amount of a pharmacologically active compound to a mammal to provide transmucosal absorption of a pharmacologically effective amount of the active compound through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising:

spraying the oral mucosa of the mammal with a buccal spray composition, containing a pharmacologically active compound dissolved in a pharmacologically acceptable solvent, comprising in weight percent of the composition:

an active compound in an amount between 0.005 and 55 percent comprising an antihistamine, alkaloid, hormone, benzodiazepine or narcotic analgesic; and

a non-polar solvent in an amount between 30 and 99 percent.